The amino acid change from a proline to an alanine reduces the activity of TYK2, lowering the potential for the cells to produce IFN-γ and IL-17, hence the minor C allele is considered MS disease-protective [12,13]. This evidence concerns the gene TYK2 and myeloid sarcoma.